LYDOLYTE Trademark

Trademark Overview

On Monday, March 7, 2022, a trademark application was filed for LYDOLYTE with the United States Patent and Trademark Office. The USPTO has given the LYDOLYTE trademark a serial number of 97299852. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, November 1, 2024. This trademark is owned by MEDRX CO., LTD.. The LYDOLYTE trademark is filed in the Pharmaceutical Products category with the following description:

Lidocaine in the form of patches and preparations
lydolyte

General Information

Serial Number97299852
Word MarkLYDOLYTE
Filing DateMonday, March 7, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, November 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 18, 2023

Trademark Statements

Goods and ServicesLidocaine in the form of patches and preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 14, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMEDRX CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKagawa 769-2712
JP
Party NameMEDRX CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKagawa 769-2712
JP

Trademark Events

Event DateEvent Description
Monday, January 9, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 10, 2022NEW APPLICATION ENTERED
Friday, March 11, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 16, 2022ASSIGNED TO EXAMINER
Monday, January 9, 2023NON-FINAL ACTION WRITTEN
Monday, January 9, 2023NON-FINAL ACTION E-MAILED
Friday, March 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 10, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 10, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 14, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, March 14, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, March 14, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, March 14, 2023EXAMINER'S AMENDMENT ENTERED
Wednesday, March 15, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 18, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 18, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, March 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 13, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 1, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 1, 2023SOU EXTENSION 1 FILED
Wednesday, November 1, 2023SOU EXTENSION 1 GRANTED
Friday, November 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 17, 2024SOU EXTENSION 2 FILED
Friday, May 17, 2024SOU EXTENSION 2 GRANTED
Friday, May 17, 2024SOU TEAS EXTENSION RECEIVED
Friday, November 1, 2024SOU TEAS EXTENSION RECEIVED
Friday, November 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 1, 2024SOU EXTENSION 3 FILED
Friday, November 1, 2024SOU EXTENSION 3 GRANTED
Saturday, May 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

lydolyte preparations patches form lidocaine